| Assessment Status |
Rapid Review Complete |
| HTA ID |
25014 |
| Drug |
Tislelizumab |
| Brand |
Tevimbra® |
| Indication |
Tislelizumab (Tevimbra®) as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy. |
| Rapid review commissioned |
18/02/2025 |
| Rapid review completed |
04/03/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tislelizumab compared with the current standard of care. |
